Last reviewed · How we verify

Thrombosis Prevention in Heparin-Induced Thrombocytopenia — Treatment Landscape & Competitive Intelligence

Thrombosis Prevention in Heparin-Induced Thrombocytopenia (disease) competitive landscape: 1 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

1 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Thrombosis Prevention in Heparin-Induced Thrombocytopenia, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Argatroban ARGATROBAN Hikma Pharm Co Ltd Anti-coagulant [EPC] Prothrombin 2000-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Hikma Pharm Co Ltd · 1 drug in Thrombosis Prevention in Heparin-Induced Thrombocytopenia

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Thrombosis Prevention in Heparin-Induced Thrombocytopenia:

Cite this brief

Drug Landscape (2026). Thrombosis Prevention in Heparin-Induced Thrombocytopenia — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/thrombosis-prevention-in-heparin-induced-thrombocytopenia. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing